Can plasma p-tau231 serve as a more precise early biomarker for Alzheimer's disease?

1. Why is there an urgent need for more sensitive blood biomarkers in early diagnosis of Alzheimer's disease?

Alzheimer's disease (AD) is a condition characterized by neuropathological changes that begin decades before clinical symptoms appear. Early and accurate diagnosis is crucial for disease intervention and clinical trials. Traditionally, AD diagnosis relies on cerebrospinal fluid (CSF) biomarker testing (such as Aβ42 and p-tau) or expensive positron emission tomography (PET) imaging. However, CSF collection is invasive, and PET is costly with limited accessibility, restricting their use in large-scale screening and dynamic monitoring. Therefore, developing highly sensitive and specific blood-based (plasma/serum) AD biomarkers is a core direction for achieving non-invasive, convenient, and low-cost early diagnosis and disease progression monitoring. Abnormal hyperphosphorylation of tau protein is one of the central pathological features of AD, and specific phosphorylated fragments (e.g., p-tau181, p-tau217) have shown potential for detection in blood. However, discovering earlier and more specific blood biomarkers remains a cutting-edge focus of current research.

2. Why choose p-tau231 as a potential early biomarker for exploration?

Tau protein has numerous phosphorylation sites, and the kinetics and pathophysiological significance of phosphorylation at different sites may vary. Tau protein phosphorylated at threonine 231 (p-tau231) has garnered significant attention in AD research. Preliminary CSF studies have shown that p-tau231 levels rise significantly in the early stages of AD, even shortly after amyloid pathology (Aβ) appears, potentially earlier than changes at sites like p-tau181. This characteristic suggests that plasma p-tau231 may have unique potential as a blood biomarker for very early AD pathology (i.e., "incipient" pathology). However, the concentration of p-tau231 in blood is extremely low, far below that in CSF, making reliable quantification challenging with traditional methods (e.g., conventional ELISA). This has been a major technical bottleneck hindering its clinical application.

3. How does ultrasensitive Simoa technology enable accurate quantification of plasma p-tau231?

To overcome detection sensitivity limits, this study employed digital immunoassay technology based on single-molecule arrays. This technology isolates individual immune complexes in femtoliter-sized microwells and performs digital counting, achieving detection sensitivity over 1,000 times higher than conventional methods.

The research team developed a highly specific Simoa assay for p-tau231:

- Core reagents: The key to the method lies in a pair of highly specific monoclonal antibodies. The capture antibody specifically recognizes tau peptides containing the phosphorylated Thr231 site (amino acid sequence K224…C240), ensuring only p-tau231 is captured. The detection antibody targets the N-terminal region of tau protein and is conjugated with biotin labeling. The standard is full-length tau protein phosphorylated in vitro.

- Performance validation: The method achieved a lower limit of quantification (LLOQ) of 0.25 pg/mL for plasma p-tau231, with a detection rate of 98.5% in clinical samples. This demonstrates the technology's ability to reliably quantify plasma p-tau231 at extremely low concentrations, laying a solid technical foundation for subsequent large-scale cohort studies.

4. What diagnostic performance does plasma p-tau231 exhibit across different cohort studies?

The study systematically evaluated the diagnostic value of plasma p-tau231 in multiple independent cohorts, including a discovery cohort, the memory clinic-based TRIAD cohort, a primary care cohort, and a neuropathological validation cohort.

Consistent findings include:

1. Excellent diagnostic differentiation: Plasma p-tau231 levels were significantly higher in AD dementia patients compared to cognitively normal elderly individuals, mild cognitive impairment (MCI) patients, and non-AD neurodegenerative disease patients, demonstrating strong disease differentiation.

2. High correlation with gold-standard biomarkers: Plasma p-tau231 levels showed strong positive correlations with CSF p-tau231 concentrations and PET-measured brain Aβ deposition burden. This confirms that blood p-tau231 signals accurately reflect core pathological changes in the central nervous system and are not isolated events.

3. Association with cognitive status and pathological staging: Plasma p-tau231 levels were negatively correlated with patients' global cognitive function scores and increased progressively with Braak neurofibrillary tangle pathology staging (reflecting tau pathology severity).

5. Does p-tau231 appear earlier in disease progression compared to p-tau181?

Through longitudinal and cross-sectional comparisons, the study yielded its most insightful finding: plasma p-tau231 may be an earlier pathological signal than existing biomarkers.

1. Early response in Aβ pathology: In individuals with brain Aβ deposition (Aβ-PET positive) but no dementia, plasma p-tau231 levels were significantly elevated, while plasma p-tau181 showed no significant increase. This suggests p-tau231 may respond to AD pathology as early as the "Aβ-positive but cognitively normal" stage.

2. Earlier differentiation of pathological stages: When patients were grouped by Braak staging, plasma p-tau231 showed diagnostic value at stages I-II (very early), while significant increases in plasma p-tau181 occurred at later stages III-IV. This indicates p-tau231 can identify individuals at earlier tau pathology stages.

3. Leading role in dynamic progression: When quantifying disease progression in Aβ-PET positive individuals, plasma p-tau231 showed significant increases at earlier segments (Q2), while plasma p-tau181 and CSF p-tau217 increases appeared at later segments (Q3).

6. The core value of p-tau231 antibodies in research and translation

The entire process from concept validation to performance establishment in this study heavily relied on specific p-tau231 antibodies. Their value is reflected in:

1. Foundation for assay development: High-affinity, highly specific capture and detection antibody pairs are the absolute core for building ultrasensitive Simoa assays, determining the specificity and sensitivity limits.

2. Tools for mechanistic exploration and validation: These antibodies enabled researchers to accurately quantify p-tau231 in plasma for the first time and correlate it with imaging, pathology, and clinical endpoints, validating its hypothesis as an early biomarker.

3. Prerequisite for future clinical applications: If plasma p-tau231 detection is to be translated into a clinical diagnostic tool, its kit must be based on rigorously validated, stable-performance p-tau231 antibodies. These antibodies ensure standardized, reproducible detection.

7. Which vendors provide p-tau231 antibodies?

Hangzhou Start Biotech Co., Ltd. has independently developed the "Tau (phospho T231) Mouse Monoclonal Antibody (SDT-202-2)" (Catalog No.: S0B3220), a phosphorylation-specific detection antibody with high specificity, high affinity, and excellent application stability. This product is produced using hybridoma technology and specifically recognizes human tau protein phosphorylated at threonine 231 (Thr231) (p-Tau231), with minimal cross-reactivity to non-phosphorylated tau or other phosphorylation sites. The antibody performs exceptionally well in Western blot (WB), immunohistochemistry (IHC), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA), making it a key tool for pathological research in Alzheimer's disease (AD) and other tauopathies, early diagnostic biomarker development, and drug efficacy evaluation.

Technical support: We provide detailed technical documentation for this antibody, including specificity validation data, recommended experimental protocols for different platforms (WB/IHC/IF), representative result images, and references. Our technical team offers professional consultation to assist in addressing challenges encountered in neuroscience research and in vitro diagnostic development.

Hangzhou Start Biotech Co., Ltd. is committed to providing high-quality, high-value antibody tools and solutions for global neuroscience research, neurodegenerative disease diagnosis, and treatment. For more information about the "Tau (phospho T231) Mouse Monoclonal Antibody" (Catalog No. S0B3220), to access validation data, or to request sample testing, please feel free to contact us.

Product Information